Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies Meeting Abstract
| Authors: | Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; Atwal, S. K.; Hong, W.; Assouline, S. E. |
| Abstract Title: | Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 834 |
| End Page: | 835 |
| Language: | English |
| DOI: | 10.1002/hon.3166_OT15 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: OT15 -- Source: Cinahl |
